| Biomarker ID | 481 |
| PMID | 19854485 |
| Year | 2010 |
| Biomarker | Clusterin Density |
| Biomarker Basis | Concentration Based (μg/ml) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Decreased expression in Patients with Biochemical Recurrence free Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Myc repressed pathway,Response to elevated platelet cytosolic calcium,Platelet activation, signaling and aggregation,BDNF signaling pathway,FSH regulation of apoptosis |
| Experiment | Biochemical Recurrence Free Survival Vs No Survial |
| Type of Biomarker | Prognostic |
| Cohort | Sera were obtained from 380 patients with prostate cancer and 120 with benign prostatic hyperplasia. Of the 380 prostate cancer patients, 162 underwent radical prostatectomy and pelvic lymphadenectomy. Only those 162 (adical prostatectomy) patients were covered for this case study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.034 |
| Method Used | sandwich enzyme immunoassay |
| Clinical | No |
| Remarks | Clusterin density was determined by dividing the serum clusterin level by the prostate volume |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CLU |